中創環球(01678.HK):吳宜華5月28日提出解散第二呈請
格隆匯5月31日丨中創環球(01678.HK)公吿,參考公司在2021年5月18日發佈的公吿中所披露的,公司接獲吳宜華,根據公司清盤程序2021年第50號向高等法院提交呈請內容關於公司可能因公司無力償債及未能支付其債務共港元216.57萬而被高等法院清盤("第二呈請")。
公司董事會欣然地吿,吳宜華律師於2021年5月28日向高等法院提交同意傳票,提出解散第二呈請,並撤銷定於2021年6月2日的第二呈請聆訊。
公司及其法律顧問將盡快與姚提出方案解決其呈請。公司將根據上市規則於適當時候作出進一步公吿。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.